Table 2.
Results of the cost-effectiveness analysis: base-case, lifelong time horizon
| Outcome | Inclisiran | Comparator | Difference |
|---|---|---|---|
| Life-expectancy | |||
| Life-years per person | 11.416 | 11.217 | 0.199 |
| Life-year difference per person treated with inclisiran | – | – | 0.364 |
| QALYs | |||
| QALYs per person | 8.485 | 8.326 | 0.159 |
| QALY difference per person treated with inclisiran | – | – | 0.291 |
| Costs and ICER at inclisiran price CHF 500 | |||
| Cost per person (CHF) | 97,731 | 94,377 | 3354 |
| Cost difference per person treated with inclisiran (CHF) | – | – | 6144 |
| ICER (CHF per life-year gained) | – | – | 16,875 |
| ICER (CHF per QALY gained) | – | – | 21,107 |
| Costs and ICER at inclisiran price CHF 3000 | |||
| Cost per person (CHF) | 130,610 | 94,377 | 36,233 |
| Cost difference per person treated with inclisiran (CHF) | – | – | 66,375 |
| ICER (CHF per life-year gained) | – | – | 182,318 |
| ICER (CHF per QALY gained) | – | – | 228,040 |
Modelled outcomes were cumulated starting from age 40 years through end of life for a cohort of real-world Swiss cardiovascular secondary prevention patients (including first-year prevalent cases and new incident cases from that year) representing 302,738 patients. In the inclisiran strategy, reflecting the assumed treatment eligibility criteria, 55% of the cohort were treated with inclisiran. QALYs and costs were discounted at 3%. See text and ESM for details on the model and calculations
CHF Swiss francs, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year